| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenue: | |||||||||
Sale of products, net | |||||||||
- | - | - | - | 8,521 | 528 | 278 | - | - | - |
Royalties from licensing | |||||||||
- | - | - | - | - | - | 7,000 | 0 | - | - |
Other income - therapeutic grant | |||||||||
- | - | - | - | - | - | - | - | 223 | - |
Sale of products, net | |||||||||
25,832 | 26,426 | 16,600 | 12,279 | - | - | 7,278 | - | 1,012 | 49 |
Cost of goods sold (exclusive of depreciation shown separately below): | |||||||||
Sale of products | |||||||||
- | - | - | - | - | - | - | 18 | - | - |
Total Revenue | |||||||||
- | - | - | - | - | - | - | 18 | 788 | 49 |
Products | |||||||||
- | - | - | - | 9,102 | 252 | 48 | 67 | 418 | 27 |
Royalties for licensing | |||||||||
- | - | - | - | - | 246 | 413 | 0 | - | - |
Cost of Revenue | |||||||||
- | - | - | - | - | 498 | 461 | 67 | - | - |
Products | |||||||||
25,818 | 25,527 | 17,308 | 12,709 | - | - | - | - | - | - |
Gross profit (loss) | |||||||||
14 | 898 | -707 | -429 | -580 | 30 | 6,816 | -49 | - | - |
Operating expenses: | |||||||||
Research and development (including equity-based compensation of $41 and $100, respectively) | |||||||||
8,057 | 14,989 | 3,366 | 2,340 | 1,571 | 1,216 | 744 | 729 | 2,097 | 363 |
Sales, general and administrative (including equity-based compensation of $439 and $349, respectively) | |||||||||
12,956 | 8,585 | 8,278 | - | - | - | - | - | - | - |
Impairment | |||||||||
1,142 | 0 | 0 | - | - | - | - | - | - | - |
General and administrative (including equity-based compensation) | |||||||||
- | - | - | 6,193 | 7,760 | 8,823 | 4,106 | 2,205 | 1,785 | 590 |
Pre-manufacturing facility costs (including equity based compensation of $0, $0 and $27,923, respectively) | |||||||||
- | - | - | - | - | 1,176 | 0 | - | - | - |
Sales and marketing costs (including equity-based compensation) | |||||||||
- | - | - | 1,581 | 1,357 | 85 | 9 | 61 | 286 | - |
Depreciation | |||||||||
589 | 522 | 353 | 326 | 319 | 230 | 3 | - | - | - |
Amortization | |||||||||
835 | 819 | 593 | 516 | 454 | 265 | 141 | - | - | - |
Amortization and depreciation | |||||||||
- | - | - | - | - | - | - | 198 | 179 | 164 |
Total operating expenses | |||||||||
23,580 | 24,917 | 12,591 | 10,958 | 11,463 | 11,797 | 5,004 | - | - | - |
Total operating expenses | |||||||||
- | - | - | - | - | - | - | 3,194 | 4,767 | 1,147 |
Operating loss | |||||||||
-23,566 | -24,018 | -13,299 | -11,387 | -12,043 | -11,767 | 1,812 | -3,244 | -3,755 | -1,097 |
Other income (expense): | |||||||||
Unrealized (loss) gain on investment | |||||||||
-2,419 | 284 | 342 | -202 | - | - | - | - | - | - |
Realized gain on investments | |||||||||
0 | 14,492 | 0 | 0 | - | - | - | - | - | - |
Realized (loss) on short-term investment securities | |||||||||
220 | -54 | 0 | 0 | - | - | - | - | - | - |
Litigation expense | |||||||||
1,890 | 0 | 0 | - | - | - | - | - | - | - |
Warrant liability loss - net | |||||||||
- | - | - | - | - | - | - | -1,998 | - | - |
Warrant amendment inducement expense | |||||||||
- | - | - | - | - | 144 | 3,736 | 0 | - | - |
Settlement Proceeds | |||||||||
- | - | - | - | 1,000 | 0 | 0 | - | - | - |
Loss on the disposition of machinery and equipment | |||||||||
- | - | - | - | -15 | 71 | 0 | - | - | - |
Gain (loss) on investment | |||||||||
- | - | - | - | -95 | -101 | 0 | - | - | - |
Unrealized loss on short-term investment securities | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Gain on the sale of machinery and equipment | |||||||||
87 | 0 | 0 | - | - | - | - | - | - | - |
Warrant liability gain (loss), net | |||||||||
0 | 48 | -157 | 29 | 144 | -3,676 | -23,602 | - | - | - |
Dividend income | |||||||||
0 | 221 | 0 | 0 | - | - | - | - | - | - |
Income tax credit refund | |||||||||
- | - | - | - | - | - | -122 | 0 | - | - |
Interest income, net | |||||||||
1,066 | 1,069 | 115 | 16 | 31 | 30 | 0 | - | - | - |
Interest expense | |||||||||
56 | 10 | 29 | 37 | 52 | 7 | 748 | - | - | - |
Warrant liability (loss) gain - net | |||||||||
- | - | - | - | - | - | - | - | 2,511 | - |
Related parties | |||||||||
- | - | - | - | - | - | - | 272 | 45 | 265 |
Other | |||||||||
- | - | - | - | - | - | - | 1,221 | 58 | 61 |
Total other income (expense) | |||||||||
-2,992 | 16,051 | 270 | -193 | 1,011 | -3,827 | -27,965 | -3,492 | 2,407 | -326 |
Loss before income taxes | |||||||||
-26,558 | -7,966 | -13,029 | -11,581 | -11,031 | -15,595 | -26,153 | - | - | - |
Income taxes - deferred | |||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
Net loss attributable to non-controlling interest | |||||||||
- | - | - | - | - | - | - | -1 | 6 | -0 |
Net loss | |||||||||
-26,558 | -7,966 | -13,029 | -11,581 | -11,031 | -15,595 | -26,153 | -6,735 | -1,353 | -1,423 |
Other comprehensive (loss) income: | |||||||||
Unrealized (loss) gain on short-term investment securities | |||||||||
206 | -21 | 0 | 0 | - | - | - | - | - | - |
Reclassification of losses to net loss | |||||||||
220 | -43 | 0 | 0 | - | - | - | - | - | - |
Other comprehensive income (loss) | |||||||||
-14 | 21 | 0 | 0 | - | - | - | - | - | - |
Comprehensive loss | |||||||||
-26,572 | -7,945 | -13,029 | -11,581 | - | - | - | - | - | - |
Net loss | |||||||||
- | - | - | - | - | - | - | -6,736 | -1,347 | -1,423 |
Net loss per common share - basic and diluted | |||||||||
-0.21 | -0.06 | -0.13 | -0.15 | -0.16 | -0.26 | -0.60 | -0.22 | -0.05 | -0.11 |
Common shares used in basic and diluted net loss per share calculation | |||||||||
125,882 | 124,298 | 101,161 | 79,842 | 68,143 | - | - | - | - | - |
Common shares used in basic net (loss) income per share calculation | |||||||||
- | - | - | - | - | 59,993 | 43,635 | 30,419 | 26,391 | 12,437 |